Publication date: March 2017
Source:International Journal of Pediatric Otorhinolaryngology, Volume 94
Author(s): Matthew G. Crowson, Marisa A. Ryan, Vaibhav H. Ramprasad, Kevin J. Choi, Eileen Raynor
ObjectivesPediatric patient caregivers may prefer to avoid a surgical intervention and request a medical management option for eustachian tube dysfunction (ETD). However, there are limited published data evaluating the efficacy of intranasal fluticasone in the medical management of ETD as an alternative to tympanostomy tube placement. The objectives of this study were to: 1) determine if intranasal fluticasone (INF) prevented tympanostomy tube placement in children with ETD, and 2) describe differences in patient response to INF related to cleft lip and/or palate (CLP) and Down syndrome.MethodsCase series with planned chart review at a Tertiary academic hospital. We reviewed pediatric patients treated with INF for ETD. Inclusion criteria included ETD, no prior intranasal or oral steroid therapy, and no prior tympanostomy tube placement. Outcomes included time-to- tympanostomy tube placement with or without INF and therapy compliance. Kaplan-Meier survival analyses with log-rank tests and Fisher's exact tests were used to examine outcome variables.Results676 fulfilled inclusion criteria. 393 (58.7%) were male, and 355 (52.5%) Caucasian with mean age of 27.1 months old. 92 (13.6%) had CLP and 46 (6.8%) had Down Syndrome. 266 (39.4%) received INF, and 202 (88.2%) were compliant at their next visit. 474 (70.1%) had tympanostomy tubes placed. Children treated with INF were less likely to have tympanostomy tubes placed than children not treated (52.6% vs. 81.5%; p < 0.0001). Using survival analyses, INF use was associated with significantly longer mean time-to-tympanostomy tube than no INF use (199.4 vs. 133.7 days; p < 0.0001). INF did not reduce time-to-tympanostomy tube in patients with CLP (p = 0.05) or Down Syndrome (p = 0.27).ConclusionINF significantly reduces the number of children requiring tympanostomy tube placement for ETD. The CLP and Down Syndrome anatomical variants may attenuate INF efficacy. Further in vivo characterization of INF action on eustachian tube tissues will help further substantiate these observations.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jDOnQs
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This case report outlines the possibility of accelerated tooth movement with the combination of microosteoperforation and mini-screws. A 14-...
-
by Rebekah L. Rogers, Ling Shao, Kevin R. Thornton One common hypothesis to explain the impacts of tandem duplications is that whole gene ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2juls25 via IFTTT
-
by Qi Quan, Lei Hong, Biao Chang, Ruoxi Liu, Yun Zhu, Jiang Peng, Qing Zhao, Shibi Lu Purpose The purpose of this study was to simulate and...
-
A critical step in cellular-trafficking pathways is the budding of membranes by protein coats, which recent experiments have demonstrated ca...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The secondary channel (SC) of multisubunit RNA polymerases (RNAPs) allows access to the active site and is a nexus for the regulation of tra...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
-
ACS Nano DOI: 10.1021/acsnano.6b06114 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kOsUGq via...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου